Drug profile · INN
autologous cartilage-derived articular chondrocytes, in-vitro expanded
JELRIX
autologous cartilage-derived articular chondrocytes, in-vitro expanded (JELRIX) is an FDA-listed pharmaceutical active ingredient.
EMA: application withdrawn Musculo-skeletal system (M09) M09AX02
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — autologous cartilage-derived articular chondrocytes, in-vitro expanded
- Class
- Musculo-skeletal system (M09)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
autologous cartilage-derived articular chondrocytes, in-vitro expanded (JELRIX) is an FDA-listed pharmaceutical active ingredient.
Key facts
INN autologous cartilage-derived articular chondrocytes, in-vitro expanded
Brand JELRIX
Therapeutic class Musculo-skeletal system (M09)
ATC code M09AX02
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | application withdrawn | — |
Related & competitor drugs
Frequently asked questions
What is autologous cartilage-derived articular chondrocytes, in-vitro expanded?
autologous cartilage-derived articular chondrocytes, in-vitro expanded (JELRIX) is an FDA-listed pharmaceutical active ingredient.
What is the brand name for autologous cartilage-derived articular chondrocytes, in-vitro expanded?
JELRIX is a marketed brand name for autologous cartilage-derived articular chondrocytes, in-vitro expanded. Check FDA Drugs@FDA for the current US label holder and prescribing information.